
Tris Pharma Reveals Strong Safety and Efficacy Data for Cebranopadol, a New Pain Therapy
Tris Pharma, Inc., a biopharmaceutical company specializing in ADHD, pain, addiction, and neurological disorders, has announced new clinical data showcasing that cebranopadol, a dual nociceptin/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor agonist, causes significantly less respiratory depression…












